Limits...
Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients.

Yin JY, Huang Q, Zhao YC, Zhou HH, Liu ZQ - PLoS ONE (2012)

Bottom Line: Publications were selected from PubMed, Cochrane Library and ISI Web of Knowledge.Data were extracted from 24 publications, which included 11 polymorphisms in 8 genes for meta-analysis.Attention should be paid to MDR1 C3435T, G2677A/T and GSTP1 A313G for personalized chemotherapy treatment for NSCLC patients in Asian population in the future.

View Article: PubMed Central - PubMed

Affiliation: Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, China.

ABSTRACT

Aim: To determine the pharmacogenetics of platinum-based chemotherapy in Non Small Cell Lung Cancer (NSCLC) patients.

Methods: Publications were selected from PubMed, Cochrane Library and ISI Web of Knowledge. A meta-analysis was conducted to determine the association between genetic polymorphisms and platinum-based chemotherapy by checking odds ratio (OR) and 95% confidence interval (CI).

Results: Data were extracted from 24 publications, which included 11 polymorphisms in 8 genes for meta-analysis. MDR1 C3435T (OR = 1.97, 95% CI: 1.11-3.50, P = 0.02), G2677A/T (OR = 2.61, 95% CI: 1.44-4.74, P = 0.002) and GSTP1 A313G (OR = 0.32, 95% CI: 0.17-0.58, P = 0.0002) were significantly correlated with platinum-based chemotherapy in Asian NSCLC patients.

Conclusion: Attention should be paid to MDR1 C3435T, G2677A/T and GSTP1 A313G for personalized chemotherapy treatment for NSCLC patients in Asian population in the future.

Show MeSH

Related in: MedlinePlus

Meta-analysis of association between MDR1 C3435T and platinum-based chemotherapy in overall (A), Asian (B) and Caucasian (C) NSCLC patients.Significant association was identified in overall (P = 0.008) and Asian (P = 0.02) populations.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3383686&req=5

pone-0038150-g005: Meta-analysis of association between MDR1 C3435T and platinum-based chemotherapy in overall (A), Asian (B) and Caucasian (C) NSCLC patients.Significant association was identified in overall (P = 0.008) and Asian (P = 0.02) populations.

Mentions: Five studies investigated MDR1 C3435T, including a total of 379 patients, the response rates in the CC and CT+TT genotype group were 51.2% and 37.6%, respectively. No heterogeneity across the studies was found (P = 0.77, I2 = 0%). We thus selected fixed-effect model. The result showed that this polymorphism was significantly correlated with drug response (OR = 1.82, 95% CI: 1.17−2.85, P = 0.008) (Figure 5A). CC genotype carrier showed significant increased drug response. Considering that ethnic differences between populations may contribute to the drug response and our included five studies comprise two different ethnic populations, we further conducted separate analyses in Asian and Caucasian population, respectively. It was interesting to note that MDR1 C3435T was only significantly correlated with platinum response in Asian population (P = 0.02) (Figure 5B). No association was detected in Caucasian population (P = 0.19) (Figure 5C).


Meta-analysis on pharmacogenetics of platinum-based chemotherapy in non small cell lung cancer (NSCLC) patients.

Yin JY, Huang Q, Zhao YC, Zhou HH, Liu ZQ - PLoS ONE (2012)

Meta-analysis of association between MDR1 C3435T and platinum-based chemotherapy in overall (A), Asian (B) and Caucasian (C) NSCLC patients.Significant association was identified in overall (P = 0.008) and Asian (P = 0.02) populations.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3383686&req=5

pone-0038150-g005: Meta-analysis of association between MDR1 C3435T and platinum-based chemotherapy in overall (A), Asian (B) and Caucasian (C) NSCLC patients.Significant association was identified in overall (P = 0.008) and Asian (P = 0.02) populations.
Mentions: Five studies investigated MDR1 C3435T, including a total of 379 patients, the response rates in the CC and CT+TT genotype group were 51.2% and 37.6%, respectively. No heterogeneity across the studies was found (P = 0.77, I2 = 0%). We thus selected fixed-effect model. The result showed that this polymorphism was significantly correlated with drug response (OR = 1.82, 95% CI: 1.17−2.85, P = 0.008) (Figure 5A). CC genotype carrier showed significant increased drug response. Considering that ethnic differences between populations may contribute to the drug response and our included five studies comprise two different ethnic populations, we further conducted separate analyses in Asian and Caucasian population, respectively. It was interesting to note that MDR1 C3435T was only significantly correlated with platinum response in Asian population (P = 0.02) (Figure 5B). No association was detected in Caucasian population (P = 0.19) (Figure 5C).

Bottom Line: Publications were selected from PubMed, Cochrane Library and ISI Web of Knowledge.Data were extracted from 24 publications, which included 11 polymorphisms in 8 genes for meta-analysis.Attention should be paid to MDR1 C3435T, G2677A/T and GSTP1 A313G for personalized chemotherapy treatment for NSCLC patients in Asian population in the future.

View Article: PubMed Central - PubMed

Affiliation: Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha, China.

ABSTRACT

Aim: To determine the pharmacogenetics of platinum-based chemotherapy in Non Small Cell Lung Cancer (NSCLC) patients.

Methods: Publications were selected from PubMed, Cochrane Library and ISI Web of Knowledge. A meta-analysis was conducted to determine the association between genetic polymorphisms and platinum-based chemotherapy by checking odds ratio (OR) and 95% confidence interval (CI).

Results: Data were extracted from 24 publications, which included 11 polymorphisms in 8 genes for meta-analysis. MDR1 C3435T (OR = 1.97, 95% CI: 1.11-3.50, P = 0.02), G2677A/T (OR = 2.61, 95% CI: 1.44-4.74, P = 0.002) and GSTP1 A313G (OR = 0.32, 95% CI: 0.17-0.58, P = 0.0002) were significantly correlated with platinum-based chemotherapy in Asian NSCLC patients.

Conclusion: Attention should be paid to MDR1 C3435T, G2677A/T and GSTP1 A313G for personalized chemotherapy treatment for NSCLC patients in Asian population in the future.

Show MeSH
Related in: MedlinePlus